1-[(2Z)-2-{[7-fluoro-5-methoxy-2-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indol-3-yl]methylidene}-3-oxo-2,3-dihydro-1-benzofuran-5-yl]-3-methylurea | 1200537-00-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-[(2Z)-2-{[7-fluoro-5-methoxy-2-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indol-3-yl]methylidene}-3-oxo-2,3-dihydro-1-benzofuran-5-yl]-3-methylurea
• 英文别名: (Z)-1-(2-((7-fluoro-5-methoxy-2-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indol-3-yl)methylene)-3-oxo-2,3-dihydrobenzofuran-5-yl)-3-methylurea；1-[(2Z)-2-[[7-fluoro-5-methoxy-2-(1,3,5-trimethylpyrazol-4-yl)-1H-indol-3-yl]methylidene]-3-oxo-1-benzofuran-5-yl]-3-methylurea
• CAS: 1200537-00-3
• 化学式: C₂₆H₂₄FN₅O₄
• 分子量: 489.506
• InChiKey: QVKXSOFEMBBXIZ-NHDPSOOVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  36
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-methyl-3-(3-oxo-2,3-dihydro-1-benzofuran-5-yl)urea 、 7-fluoro-5-methoxy-2-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-3-carbaldehyde 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 生成 1-[(2Z)-2-{[7-fluoro-5-methoxy-2-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indol-3-yl]methylidene}-3-oxo-2,3-dihydro-1-benzofuran-5-yl]-3-methylurea
  参考文献：
  名称：

  5-Ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-α and mTOR for the treatment of breast cancer

  摘要：

  A series of 5-ureidobenzofuran-3-one indoles as potent inhibitors of PI3K alpha and mTOR has been developed. The best potency in cells was obtained when the urea group was extended to a 4-[2-(dimethylamino)ethyl]methylamino amidophenyl group. A 7-fluoro group on the indole ring also enhanced cellular potency. Compound 18i, incorporating the optimal functional groups, showed high potency in cellular lines and was further studied in vivo. It was able to inhibit the biomarker phosphorylation for 8 h when dosed at 25 mg/kg iv. In the MDA-MB-361 breast cancer model, it shrank the tumor size remarkably when dosed at 25 mg/kg iv on days 1, 5, and 9. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.139

文献信息

• 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
  申请人：Bursavich Matthew Gregory

  公开号：US20090311217A1

  公开（公告）日：2009-12-17

  The invention relates to 3-substituted-1H-indole compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

  本发明涉及公式I的3-取代-1H-吲哚化合物或其药学上可接受的盐，其中组成变量如本文所定义，包括该化合物的组合物，以及制备和使用该化合物的方法。
• [EN] 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES<br/>[FR] COMPOSÉS DE 1H-INDOLE 3 SUBSTITUÉS, LEUR UTILISATION EN TANT QU'INHIBITEURS DE 3MTOR KINASE ET P13 KINASE, ET LEURS SYNTHÈSES
  申请人：WYETH CORP

  公开号：WO2009155042A1

  公开（公告）日：2009-12-23

  The invention relates to 3-substituted-1 H-indole compounds of the Formula (I): or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds for the treatment of PI3 and mTOR kinase-mediated diseases, e.g. cancer.
• 5-Ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-α and mTOR for the treatment of breast cancer
  作者：Nan Zhang、Semiramis Ayral-Kaloustian、James T. Anderson、Thai Nguyen、Sasmita Das、Aranapakam M. Venkatesan、Natasja Brooijmans、Judy Lucas、Ker Yu、Irwin Hollander、Robert Mallon

  DOI：10.1016/j.bmcl.2010.04.139

  日期：2010.6

  A series of 5-ureidobenzofuran-3-one indoles as potent inhibitors of PI3K alpha and mTOR has been developed. The best potency in cells was obtained when the urea group was extended to a 4-[2-(dimethylamino)ethyl]methylamino amidophenyl group. A 7-fluoro group on the indole ring also enhanced cellular potency. Compound 18i, incorporating the optimal functional groups, showed high potency in cellular lines and was further studied in vivo. It was able to inhibit the biomarker phosphorylation for 8 h when dosed at 25 mg/kg iv. In the MDA-MB-361 breast cancer model, it shrank the tumor size remarkably when dosed at 25 mg/kg iv on days 1, 5, and 9. (C) 2010 Elsevier Ltd. All rights reserved.